Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

A Randomized, Placebo-Controlled, Double Blind, Phase 1 Trial of the Safety, Immunogenicity, and Tolerability of Ascending Doses of Meningococcal Group B rLP2086 Vaccine in Healthy Adults

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00297687

Enrollment

108

Registered

2006-02-28

Start date

2006-03-31

Completion date

2007-03-31

Last updated

2007-12-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Meningitis, Meningococcal

Keywords

Vaccines, Healthy Adults, Health, Adult, Meningococcal Vaccines

Brief summary

To determine the safety & immunogenicity of a potential vaccine against meningococcal B disease

Interventions

BIOLOGICALMnB rLP2086

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE

Eligibility

Sex/Gender

ALL

Age

18 Years to 25 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy 18-25 year olds

Exclusion criteria

* Prior history of vaccination with any meningococcal vaccine * Prior history of any invasive meningococcal disease

Design outcomes

Primary

Measure	Time frame
Local & systemic safety throughout the trial	—

Secondary

Measure	Time frame
Evidence of an immune response 1 month after dose 2 & 1 month after dose 3	—

Countries

Australia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026